BOTHELL, Wash., March 27, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) today announced that it will host a conference call and simultaneous webcast Monday, March 28, 2016, at 8:30 a.m. ET, to review top-line data from its Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine and top-line data from its Phase 1 clinical trial evaluating multiple doses of ALD403 through various modes of administration in healthy volunteers.
Conference Call Details
The live call may be accessed by dialing 877-430-4657 for domestic callers or 484-756-4339 for international callers, and providing conference ID number 80096426.
The webcast, with slides, will be broadcast live on the Events & Presentations page of the Investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 firstname.lastname@example.org email@example.com Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 firstname.lastname@example.org
Source:Alder Biopharmaceuticals, Inc.